D R Burton Healthcare v. Trudell Medical — Supreme Court Petition Denied in 98 Days
D R Burton Healthcare LLC sought U.S. Supreme Court review of a patent infringement dispute against Trudell Medical International Inc. over US9808588B1, a patent covering oscillating positive respiratory pressure (OPEP) device technology. The Court denied the petition after just 98 days, foreclosing further federal judicial review for the petitioner.
Supreme Court slams the door on OPEP device patent challenge
D R Burton Healthcare LLC filed a petition for a writ of certiorari at the U.S. Supreme Court on June 30, 2025, seeking review of a patent infringement dispute against Trudell Medical International Inc. The case, docketed as No. 25-17 in the District of Columbia, centres on US9808588B1 — a U.S. patent directed to oscillating positive expiratory pressure (OPEP) respiratory device technology. Trudell Medical, represented by Crowell & Moring LLP, is a well-established player in the respiratory therapy device sector.
The Supreme Court denied the petition on October 6, 2025, just 98 days after filing. A denial of certiorari is not a ruling on the merits; it means the Court declined to hear the case, leaving the lower court’s decision intact. The basis of termination is recorded as ‘Petition Dismissed,’ which is consistent with a standard cert denial procedural disposition. D R Burton Healthcare exhausts its federal appellate options at this stage.
The 98-day timeline from filing to denial is relatively swift, suggesting the Court found no compelling reason to grant review — such as a circuit split or a question of significant federal importance. What drove the underlying infringement dispute, and what the lower court found, is not fully disclosed in the public Supreme Court docket. The denial leaves Trudell Medical’s position — and the enforceability of US9808588B1 as it relates to this dispute — unaffected by further challenge from this petitioner.
Filing to Petition Dismissed in 98 days
98-day disposition — faster than the typical Supreme Court cert cycle of 3–6 months
Supreme Court denies cert: what the ruling means for both parties
Cert denied: the Court chose not to intervene
A denial of certiorari by the U.S. Supreme Court means the Court declined to exercise its discretionary jurisdiction to review the case. It is not a ruling on the merits of the patent infringement claims. The lower court’s decision — whatever it held — remains the operative legal outcome. Fewer than 2% of petitions filed each Term are granted, making denial the statistical norm rather than an exceptional outcome.
No merits adjudication by SCOTUSTrudell Medical: lower-court position fully preserved
For Trudell Medical International, the cert denial is a complete procedural victory at the Supreme Court level. The lower court’s findings — whether relating to validity, enforceability, or non-infringement of US9808588B1 — stand undisturbed. Trudell can continue to rely on the prior ruling without the uncertainty of ongoing federal litigation from D R Burton Healthcare. The respondent’s IP position in the OPEP device space is effectively confirmed for this dispute.
Lower decision preserved for respondentD R Burton Healthcare: federal judicial options exhausted
The cert denial forecloses further federal court review for D R Burton Healthcare in this dispute. Having reached the Supreme Court, the petitioner has no higher federal tribunal to approach. While the denial carries no precedential weight on the underlying merits, it signals that the Court found no basis — such as a circuit split or novel legal question — sufficient to warrant review. Any future path forward would likely require new proceedings or different legal theories.
No further federal appeal availableOPEP device sector: patent enforcement bar remains high
The Supreme Court’s non-intervention leaves the patent litigation landscape for oscillating positive respiratory pressure devices unchanged by this case. Competitors in the OPEP device market — including those developing flutter valve, high-frequency oscillation, or airway clearance technologies — should note that US9808588B1 survives this challenge without judicial dilution. Freedom-to-operate assessments for products in this space should account for the patent’s continuing enforceability.
US9808588B1 enforceability intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | D R Burton Healthcare LLC | Company | Healthcare device company — petitioner asserting US9808588B1 covering OPEP respiratory devicesSearch in Eureka ↗ |
| Defendant | Trudell Medical International Inc. | Company | Trudell Medical International Inc. — respiratory therapy device manufacturer and patent respondentSearch in Eureka ↗ |
| Plaintiff counsel | Albert P. Allan | Attorney | Counsel for D R Burton Healthcare LLCSearch in Eureka ↗ |
| Plaintiff law firm | Allan Law Firm. PLLC | Law Firm | Representing D R Burton Healthcare LLCSearch in Eureka ↗ |
| Defendant counsel | David Paul Lindner | Attorney | Counsel for Trudell Medical International Inc.Search in Eureka ↗ |
| Defendant law firm | Crowell & Moring, LLP | Law Firm | Representing Trudell Medical International Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
Official order — verbatim text
The Supreme Court’s one-word disposition — ‘Petition DENIED’ — carries a precise but limited legal meaning. It is a discretionary refusal to hear the case, not an endorsement or rejection of any argument made by either party on the merits of the infringement dispute. Under established Supreme Court practice, a cert denial cannot be cited as precedent and does not constitute a ruling on the validity or scope of US9808588B1. The lower tribunal’s decision remains the operative authority, and Trudell Medical retains whatever rights and protections that decision conferred.
US9808588B1 — Oscillating Positive Respiratory Pressure Device
US9808588B1 is a granted U.S. utility patent filed under application number US15/453767, covering an oscillating positive respiratory pressure device. OPEP devices are therapeutic tools used to mobilise mucus in the airways, commonly prescribed for patients with chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchiectasis. The patent’s B1 designation indicates it was granted without any post-grant amendment, suggesting a prosecution history that proceeded to allowance without reissue proceedings.
Oscillating PEP technology is a competitive segment within the broader respiratory therapy device market, with several established manufacturers holding overlapping patent positions. US9808588B1’s survival through Supreme Court proceedings — without judicial scrutiny of its merits — means the patent retains full presumptive validity under 35 U.S.C. § 282. For device manufacturers, distributors, and OEM partners working on airway clearance or respiratory oscillation products, this patent represents a live enforcement risk that warrants careful claim-by-claim FTO analysis.
Should your respiratory device team run an FTO against US9808588B1?
Any company developing, manufacturing, or distributing oscillating positive expiratory pressure devices in the U.S. market should treat US9808588B1 as a priority FTO target. The patent has now been the subject of infringement litigation reaching the U.S. Supreme Court, confirming that the patent holder has demonstrated a willingness to litigate aggressively. Product teams working on flutter valves, high-frequency oscillation devices, or mucus clearance systems should evaluate claim scope before committing to design or commercialisation decisions.
PatSnap Eureka’s FTO Search Agent can map the claims of US9808588B1 against your product specifications, surface relevant prior art that may support invalidity arguments, and flag related patents in Trudell Medical’s portfolio that could create additional exposure. Eureka’s prosecution history analysis can also identify claim amendments that narrow scope — potentially revealing design-around pathways. For in-house IP teams under resource pressure, this significantly accelerates the FTO workflow ahead of product launch.
Run a freedom-to-operate analysis on US9808588B1 to assess your product’s exposure
Run FTO in Eureka →Similar respiratory device patent cases at the U.S. Supreme Court
Cases involving oscillating respiratory pressure device patents at U.S. federal courts, including Supreme Court cert petitions in the medical device sector.
What this case signals for the respiratory device IP landscape
A Supreme Court cert denial in a respiratory device patent dispute sends a clear message to OPEP technology competitors and IP strategists alike.
Cert denial preserves prior ruling — no merits shield for competitors
It is critical to understand that the Supreme Court’s denial of certiorari does not validate or invalidate US9808588B1 on the merits. It simply means the lower court’s outcome stands. Companies relying on this denial as evidence that the patent is weak or unenforceable would be drawing an unsupported legal inference. A thorough FTO analysis against US9808588B1 remains essential for any OPEP device entrant.
Swift 98-day denial signals absence of circuit conflict or novel legal question
The petition was resolved in 98 days — well below average SCOTUS cert timelines. This pace typically suggests the Court identified no circuit split, no recurring issue of federal importance, and no compelling reason to intervene. For IP practitioners, this outcome is consistent with a case that, whatever its underlying facts, did not present a question the Court viewed as requiring national resolution.
D v Trudell — key questions answered
The denial means the Court declined to review the case on the merits. It is not a ruling on the validity or scope of US9808588B1. The lower court’s decision stands, and US9808588B1 retains its full presumptive validity. The patent remains enforceable, and the denial cannot be cited as precedent in future proceedings.
Yes. A cert denial does not affect the enforceability of a patent. US9808588B1 retains full legal validity under 35 U.S.C. § 282. Competitors in the OPEP device market should not interpret the Supreme Court’s non-intervention as a green light to practice the patented technology without conducting a proper freedom-to-operate analysis.
US9808588B1 was filed under application number US15/453767. The B1 designation indicates the patent was granted without post-grant amendment. The prosecution history — accessible via the USPTO Patent Center — may contain claim amendments and examiner rejections that define the scope of the claims through prosecution history estoppel, which is material to any infringement or FTO analysis.
Trudell Medical International Inc. is a Canadian-founded respiratory therapy device manufacturer with an established presence in the OPEP and airway clearance device market. D R Burton Healthcare LLC is the petitioner asserting rights under US9808588B1 in this litigation. The public record for Case No. 25-17 does not detail the underlying commercial relationship or prior proceedings between the parties.
Following a Supreme Court cert denial, the petitioner has exhausted its federal appellate options in this particular dispute. Potential paths forward — none of which are confirmed by the current record — could include inter partes review proceedings at the USPTO to challenge patent validity on different grounds, or initiating new litigation based on different claims or infringement theories. However, the public docket does not disclose any pending proceedings.
PatSnap Eureka searches patents and litigation data to answer instantly.